Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Zoetis expects its new triple combination antiparasitic to not face any competition for the time being.
The quest for animal health innovation has accelerated tremendously over recent years, as leading players develop strategies to offset the maturation of product portfolios.
Zoetis expects lower-than-projected annual revenues from Simparica Trio – the firm's new triple combination parasiticide.
Merck Animal Health is to gain the US rights to the Sentinel family of combination parasiticides for companion animals.
Minnesota-based Aurora Pharmaceutical has been given approval in the US for a generic antiparasitic for companion animals.
Zoetis has become the first major animal health player to launch its own dual pet insurance and preventative care business with the introduction of Pumpkin.
The European Medicines Agency (EMA) is taking a closer look at the environmental risk from veterinary parasiticides for companion animals.
The US FDA has suggested extra testing needs to be done to ascertain the viability of ivermectin as a COVID-19 treatment.
Ireland's Chanelle has gained US FDA authorization for a generic companion animal topical antiparasitic.
Boragen may be a relatively small organization but the start-up's roots are linked to industry leader Zoetis' former parent company Pfizer. The North Carolina-based company talked to Animal Pharm analyst Sian Lazell about its pipeline of antiparasitic, immunological and antiprotozoal programs.
Zoetis' Simparica Trio has become the first commercial combination isoxazoline for dogs in the US after receiving FDA approval.
In the video interview below, Nadia Koziar – director of global commercial development at Zoetis – speaks about the evolution of the company's antiparasitic portfolio. Ms Koziar was talking to Animal Pharm editor Joseph Harvey at the recent launch of Simparica Trio.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.